Last reviewed · How we verify
CEFOXITIN SODIUM
At a glance
| Generic name | CEFOXITIN SODIUM |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1978 |
Approved indications
Common side effects
- Thrombophlebitis
- Rash
- Urticaria
- Flushing
- Pruritus
- Eosinophilia
- Fever
- Dyspnea
- Hypotension
- Diarrhea
- Nausea
- Vomiting
Key clinical trials
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Precision Antibiotic Dosing for Appendectomy (PHASE1)
- Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy? (PHASE3)
- The Expected Advantage of Administering Prophylactic Antibiotics Using Target- Concentration Controlled Infusion (NA)
- Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (PHASE2, PHASE3)
- Duration of Perioperative Antibiotics in Pancreatoduodenectomy (NA)
- Intermittent Cefoxitin Administration Versus Loading Bolus Followed by Continuous Infusion for the Prevention of Surgical Site Infection in Colorectal Surgery (PHASE3)
- Studying the Distribution of Accessory Gene Regulator (Agr) Quorum Sensing System and the Prevalence of Linezolid and Mupirocin Resistance in Biofilm Producer/Non Producer Staphylococcus Aureus in Sohag University Hospitals (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |